Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

Vaccine

Volumn 23, Issue 32, 2005, Pages 4148-4157

  Bojang, Kalifa A ^a   Olodude, Folasade ^a   Pinder, Margaret ^a   Ofori Anyinam, Opokua ^b   Vigneron, Laurence ^b   Fitzpatrick, Steve ^b   Njie, Fanta ^a   Kassanga, Adams ^a   Leach, Amanda ^b   Milman, Jessica ^c   Rabinovich, Regina ^c   McAdam, Keith P W J ^a   Kester, Kent E ^d   Heppner, D Gray ^d   Cohen, Joe D ^b   Tornieporth, Nadia ^b   Milligan, Paul J M ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c PATH   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Phase I paediatric vaccine trials; RTS,S AS02A

Indexed keywords

ALANINE AMINOTRANSFERASE; MALARIA VACCINE; RABIES VACCINE; RTS S AS 02 A; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ARM MOVEMENT; ARTICLE; BRONCHOPNEUMONIA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG SAFETY; EDEMA; FEMALE; FEVER; GAMBIA; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION PAIN; IRRITABILITY; LYMPHADENOPATHY; MALAISE; MALARIA; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ANIMALS; ANTIBODIES, PROTOZOAN; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; GAMBIA; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME;

EID: 20444494911     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.03.019     Document Type: Article

References (14)

1. J.A. Stoute, M. Slaoui, and G. Heppner A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria N Engl J Med 336 1997 86 91
2. J.F. Doherty, M. Pinder, and N. Tornieporth A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia Am J Trop Med Hyg 61 1999 865 868
3. K.A. Bojang, P.J.M. Milligan, and M. Pinder Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial Lancet 358 2001 1927 1934
4. K.E. Kester, D.A. McKinney, and N. Tornieporth Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria J Infect Dis 183 2001 640 647
5. World Bank. World Development Report 1993: Investing in Health. Oxford: Oxford University Press; 1993.
6. A. Leach, C.J. Drakeley, and U. D'Alessandro A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants Parasite Immunol 17 1995 441 444
7. U. D'Alessandro, A. Leach, and C.J. Drakeley Efficacy trial of malaria vaccine SPf66 in Gambian infants Lancet 346 1995 462 467
8. B.M. Greenwood, and H. Pickering A review of the epidemiology and control of malaria in The Gambia, West Africa Trans R Soc Trop Med Hyg 87 Suppl. 2 1993 3 11
9. M.C. Thomson, U. D'Alessandro, and S. Bennet Malaria prevalence is inversely related to vector density in The Gambia, West Africa Trans R Soc Trop Med Hyg 88 1994 638 643
10. P.G. Smith, and R.H. Morrow Methods for field trials of interventions against tropical diseases: a toolbox 1991 Oxford University Press
11. D.M. Gordon, T.W. McGovern, and U. Krzych Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine J Infect Dis 171 1995 1576 1585
12. P. Alonso, J. Sacarlal, J. Aponte, A. Leach, and E. Macete Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial Lancet 364 2004 1411 1420
13. K.H.G. Mills Regulatory T cells: friend or foe in immunity to infection Nat Rev Immunol 4 2004 841 855
14. S. Viviani, A. Jack, and A.J. Hall Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age Vaccine 17 1999 2946 2950